Health Care & Life Sciences » Biotechnology | Orexigen Therapeutics Inc.

Orexigen Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2012
2013
2014
2015
2016
Cash & Short Term Investments
137,403.00
176,996.00
205,537.00
214,011.00
193,998.00
Total Accounts Receivable
-
-
2,571.00
6,828.00
1,102.00
Inventories
-
-
1,198.00
10,802.00
23,193.00
Other Current Assets
1,491.00
1,286.00
2,020.00
2,254.00
6,168.00
Total Current Assets
138,894.00
178,282.00
211,326.00
233,895.00
224,461.00
Net Property, Plant & Equipment
83.00
630.00
857.00
1,284.00
1,044.00
Total Investments and Advances
177.00
177.00
177.00
138.00
188.00
Intangible Assets
-
-
-
-
76,061.00
Other Assets
-
1,032.00
621.00
1,013.00
2,835.00
Total Assets
139,154.00
180,121.00
212,981.00
236,330.00
304,589.00
Accounts Payable
3,811.00
4,787.00
4,243.00
6,485.00
15,210.00
Income Tax Payable
-
-
-
1,346.00
133.00
Other Current Liabilities
21,303.00
18,066.00
25,471.00
24,410.00
50,017.00
Total Current Liabilities
25,114.00
22,853.00
29,714.00
32,241.00
65,360.00
Long-Term Debt
-
80,031.00
83,908.00
87,870.00
166,179.00
Provision for Risks & Charges
-
-
-
-
6,800.00
Deferred Taxes
-
-
547.00
-
-
Other Liabilities
38,571.00
35,375.00
76,468.00
82,841.00
5,863.00
Total Liabilities
63,685.00
138,259.00
190,637.00
202,952.00
244,202.00
Common Equity (Total)
75,469.00
41,862.00
22,344.00
33,378.00
57,044.00
Total Shareholders' Equity
75,469.00
41,862.00
22,344.00
33,378.00
60,387.00
Total Equity
75,469.00
41,862.00
22,344.00
33,378.00
60,387.00
Liabilities & Shareholders' Equity
139,154.00
180,121.00
212,981.00
236,330.00
304,589.00
Preferred Stock (Carrying Value)
-
-
-
-
3,343.00

About Orexigen Therapeutics

View Profile
Address
3344 North Torrey Pines Court
La Jolla California 92037
United States
Employees -
Website http://www.orexigen.com
Updated 09/14/2018
Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities includes recruiting personnel, conducting research and development, including clinical trials, raising capital and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA.